Mounjaro® is a prescription medication that targets two hormone pathways, GLP1 and GIP. These hormones help regulate appetite, slow digestion, and improve blood sugar control. Together, they make it easier to reduce calorie intake and achieve sustainable weight loss.
In clinical trials, people using Mounjaro alongside diet and exercise achieved an average weight loss of up to 22.5% of their starting body weight over 72 weeks. Individual results vary, and progress depends on your dose, starting weight, and lifestyle changes.
Mounjaro is generally prescribed for adults who are overweight or obese, and who may also have related health conditions such as pre-diabetes or type 2 diabetes. Your clinician will assess your medical history to confirm if itʼs the right choice for you.
Mounjaro comes in pre-filled pens with doses starting at 2.5mg, increasing in gradual steps 5mg, 7.5mg, 10mg, 12.5mg, 15mg) to help your body adjust and minimise side effects.
The most common side effects are mild and temporary, including nausea, constipation, diarrhoea, and fatigue. These usually improve as your body adapts to the medication.
Some people notice changes in appetite within the first few weeks, but weight loss typically becomes more noticeable after dose increases. Full results are best judged after several months of consistent use.
While Mounjaro helps manage appetite and portion sizes, combining it with a healthy diet and regular physical activity significantly improves results and supports long-term weight management.
Wegovy® is a GLP1 medication that mimics a natural hormone involved in appetite regulation. It helps reduce hunger, slows digestion, and supports portion control, making it easier to sustain a calorie deficit for long-term weight loss.
In clinical studies, participants lost an average of 1617% of their starting body weight over 68 weeks when Wegovy was used alongside a balanced diet and regular exercise. Results will vary depending on your lifestyle, starting weight, and adherence to treatment.
Wegovy is typically prescribed to adults with a BMI over 30, or over 27 with weight-related health concerns such as high blood pressure, type 2 diabetes, or high cholesterol. Your clinician will confirm eligibility whilst reviewing your information.
Wegovy is supplied in pre-filled pens with doses ranging from 0.25mg to 2.4mg. Youʼll usually start at the lowest dose and increase gradually over several months to minimise side effects and allow your body to adjust.
The most common side effects are mild nausea, bloating, constipation, or fatigue, especially during the early weeks. These typically improve over time. Your clinician will give you tips for managing them.
Some people notice appetite changes within the first few weeks, while visible weight loss is more noticeable after dose increases. Steady, gradual loss is expected for long-term sustainability.
No, Wegovy does not reduce the effectiveness of oral contraceptives.
Yes, combining Wegovy with healthy eating and physical activity gives the best results and helps maintain your weight loss after treatment.
Most people can start without bloodwork, but if you have diabetes, pre-diabetes, or other relevant conditions, your clinician may request recent test results to tailor your treatment plan.
Weʼll need a valid photo ID and a recent full-length photo to confirm eligibility. These images are kept securely and used only for clinical verification.
Yes, tracked delivery to your home in the UK is included.
Our support team is available by email or phone during business hours to assist with delivery questions or account updates.
At present, we only supply to eligible patients within the UK. You must complete our online consultation to confirm availability in your area.
We follow strict data protection regulations to safeguard your information. All medical records are stored securely and only accessed by authorised healthcare professionals.
Medical records are retained in line with legal requirements for your state or region. You can request more details from our support team at any time.
Mounjaro (tirzepatide) targets two key hormone pathways to curb appetite, improve blood sugar, and support long-term weight loss.
Wegovy is a once-weekly injection approved for long-term weight management - backed by real-world results and robust clinical evidence.